29 Dec 2023 |
Intimation under Regulation 30 of SEBI LODR – Update on Sale of Manufacturing Facility in
Singapore |
|
PDF 237 KB |
29 Dec 2023 |
Intimation under Reg 39 (3) of LODR |
|
PDF 525 KB |
26 Dec 2023 |
Intimation under Reg 39 (3) of LODR |
|
PDF 309 KB |
23 Dec 2023 |
Update on Stelis Biopharma’s transaction with Syngene for sale of Stelis’ Unit 3 Multi-Model
Facility in Bengaluru |
|
PDF 210 KB |
21 Dec 2023 |
Intimation under Regulation 30 of SEBI LODR – Matter relating to Trinity, South Africa |
|
PDF 304 KB |
19 Dec 2023 |
Intimation under Reg 39 (3) of LODR |
|
PDF 316 KB |
01 Dec 2023 |
Strides associate company - Stelis Biopharma announces closure of its transaction with Syngene
International Limited |
|
PDF 286 KB |
01 Dec 2023 |
Strides launches Icosapent Ethyl Acid Soft Gel Capsules in partnership with Amneal |
|
PDF 539 KB |
28 Nov 2023 |
Intimation under Reg 39 (3) of LODR |
|
PDF 413 KB |
23 Nov 2023 |
Strides receives USFDA approval for Generic Suprep® Bowel Prep Kit |
|
PDF 451 KB |
21 Nov 2023 |
Strides receives USFDA approval for Levetiracetam Oral Solution |
|
PDF 406 KB |
31 Oct 2023 |
Newspaper Advertisement – Unaudited Financial Results for quarter and half year ended September
30, 2023 |
|
PDF 1 MB |
31 Oct 2023 |
Intimation under Reg 39 (3) of LODR |
|
PDF 377 KB |
30 Oct 2023 |
Change in SMP |
|
PDF 398 KB |
30 Oct 2023 |
Q2 – Statement of Deviation/Variation for the quarter ended September 30, 2023 |
|
PDF 457 KB |
30 Oct 2023 |
Outcome of Board Meeting – Un-Audited Financial Results (Standalone & Consolidated) for quarter
and half year ended September 30, 2023 |
|
PDF 738 KB |
30 Oct 2023 |
Allotment of Shares |
|
PDF 334 KB |
30 Oct 2023 |
Strides reports Strong Q2FY24 Performance - Revenues at ₹ 10,264m and EBITDA at ₹ 1,801m |
|
PDF 2 MB |
27 Oct 2023 |
Strides announces sale of manufacturing facility in Singapore for a consideration of $15m |
|
PDF 500 KB |
25 Oct 2023 |
Intimation under Regulation 30 of SEBI Regulations, 2015 (Allotment of shares) |
|
PDF 367 KB |
25 Oct 2023 |
Intimation under Reg 39 (3) of LODR |
|
PDF 335 KB |
20 Oct 2023 |
Intimation under Regulation 30 of SEBI Regulations, 2015 (Allotment of shares) |
|
PDF 334 KB |
04 Oct 2023 |
Strides receives USFDA approval for Efavirenz, Emtricitabine & Tenofovir Disoproxil Fumurate
tablets |
|
PDF 385 KB |
03 Oct 2023 |
Strides receives USFDA approval for Icosapent Ethyl Capsules - Updated Press Release |
|
PDF 450 KB |
25 Sep 2023 |
Transaction amongst wholly-owned subsidiaries |
|
PDF 305 KB |
25 Sep 2023 |
Intimation of Scheme of Arrangement pursuant to Regulation 30 of SEBI Listing Regulations |
|
PDF 2 MB |
25 Sep 2023 |
Investor call link |
|
PDF 325 KB |
23 Sep 2023 |
Strides receives USFDA approval for Icosapent Ethyl Capsules |
|
PDF 447 KB |
15 Sep 2023 |
Strides receives tentative USFDA approval for Dolutegravir/ Lamivudine/ Tenofovir Disproxil
Fumurate tablets |
|
PDF 448 KB |
14 Sep 2023 |
Strides receives tentative USFDA approval for Dolutegravir tablets. |
|
PDF 505 KB |
09 Sep 2023 |
Strides receives USFDA approval for Sevelamer Carbonate for Oral Suspension. |
|
PDF 442 KB |
07 Sep 2023 |
Intimation under Regulation 30 of SEBI LODR - Internal Restructuring of Strides Pharma Services
Private Limited, a group entity. |
|
PDF 298 KB |
06 Sep 2023 |
Intimation under Reg 39 (3) of LODR |
|
PDF 426 KB |
01 Sep 2023 |
Intimation under Regulation 30 of SEBI Regulations, 2015 (Change in Senior Management) |
|
PDF 315 KB |
30 Aug 2023 |
Strides receives USFDA approval for Mycophenolate Mofetil for Oral Suspension |
|
PDF 447 KB |
30 Aug 2023 |
Outcome of 32nd Annual General Meeting of the Company |
|
PDF 884 KB |
29 Aug 2023 |
Intimation under Regulation 30 of SEBI Listing Regulations – Corporate Guarantees on behalf of
Stelis |
|
PDF 426 KB |
29 Aug 2023 |
Intimation under Reg 39 (3) of LODR |
|
PDF 311 KB |
28 Aug 2023 |
Proceedings of AGM |
|
PDF 497 KB |
22 Aug 2023 |
Intimation under Reg 39 (3) of LODR |
|
PDF 385 KB |
16 Aug 2023 |
Intimation under Regulation 30 of SEBI Listing Regulations (CGs and Litigations) |
|
PDF 810 KB |
05 Aug 2023 |
Newspaper Publication titled ‘Notice of 32nd Annual General Meeting, Remote E-Voting and Cut-Off
Date’ |
|
PDF 1.63 MB |
04 Aug 2023 |
Notice of the 32nd Annual General Meeting and Annual Report for FY 2022-23 |
|
PDF 6 MB |
04 Aug 2023 |
Submission of Business Responsibility & Sustainability Report for FY23 |
|
PDF 605 KB |
03 Aug 2023 |
Unaudited Financial Results for the quarter ended June 30, 2023 |
|
PDF 4 MB |
03 Aug 2023 |
Intimation under Reg 39 (3) of LODR |
|
PDF 377 KB |
02 Aug 2023 |
Intimation under SEBI (Prohibition of Insider Trading) Regulations, 2015 |
|
PDF 466 KB |
02 Aug 2023 |
Intimation of Scheme of Amalgamation under Regulation 30 of the SEBI Listing Regulations |
|
PDF 385 KB |
02 Aug 2023 |
Outcome of Board Meeting – Un-Audited Financial Results (Standalone & Consolidated) for quarter
ended June 30, 2023 |
|
PDF 629 KB |
02 Aug 2023 |
Strides reports highest ever EBITDA, INR 1,686m in Q1FY24 |
|
PDF 2 MB |
28 July 2023 |
Outcome of Postal Ballot |
|
PDF 1 MB |
19 July 2023 |
Intimation under Reg 39 (3) of LODR |
|
PDF 297 KB |
12 July 2023 |
Intimation under Reg 39 (3) of LODR |
|
PDF 381 KB |
07 July 2023 |
Allotment of shares under Strides ESOP Plan 2016 |
|
PDF 1 MB |
04 July 2023 |
Stelis Biopharma enters into a binding term sheet with Syngene International Limited to
divest its Unit 3 multi-modal facility for a gross consideration of INR 7,020 million
|
|
PDF 1 MB |
29 June 2023 |
Intimation under Reg 39 (3) of LODR
|
|
PDF 301 KB |
28 June 2023 |
Intimation under Reg 39 (3) of LODR
|
|
PDF 301 KB |
27 June 2023 |
Newspaper Advertisement - Notice of Postal Ballot dated May 25, 2023
|
|
PDF 1 MB |
26 June 2023 |
Notice of Postal Ballot dated May 25, 2023 |
|
PDF 233 KB |
26 June 2023 |
Intimation under Reg 39 (3) of LODR |
|
PDF 382 KB |
23 June 2023 |
Intimation under Reg 39 (3) of LODR |
|
PDF 369 KB |
16 June 2023 |
Intimation under Reg 39 (3) of LODR |
|
PDF 364 KB |
30 May 2023 |
Annual Secretarial Compliance Report for the year ended March 31, 2023 |
|
PDF 723 KB |
30 May 2023 |
Annual Secretarial Compliance Report for the year ended March 31, 2023 |
|
PDF 233 KB |
25 May 2023 |
Disclosure of Related Party Transactions for the half year ended March 31, 2023 |
|
PDF 233 KB |
25 May 2023 |
Disclosure of Related Party Transactions for the half year ended March 31, 2023 |
|
PDF 584 KB |
25 May 2023 |
Grant of Options under Strides ESOP Plan 2016 |
|
PDF 298 KB |
25 May 2023 |
Strides reports strong Q4FY23 results and lays the foundation for a promising FY24 |
|
PDF 2 MB |
25 May 2023 |
Outcome of Board Meeting - Audited Financial Results (Standalone & Consolidated) for quarter and
year ended March 31, 2023
|
|
PDF 826 KB |
24 May 2023 |
Newspaper Adv - Notice for transferring of equity shares to IEPF |
|
PDF 350 KB |
19 May 2023 |
Strides Puducherry facility receives Establishment Inspection Report (EIR) from USFDA confirming
the reclassification of the site from Official Action Indicated (OAI) to Voluntary Action Indicated
(VAI)
|
|
PDF 263 KB |
19 May 2023 |
Intimation under Reg 39 (3) of LODR |
|
PDF 365 KB |
18 May 2023 |
Intimation of Board Meeting scheduled on May 25, 2023 |
|
PDF 325 KB |
3 May 2023 |
Strides and Orbicular enter into a strategic partnership to jointly develop a range of nasal
sprays
|
|
PDF 3.3 MB |
24 Apr 2023 |
Intimation under Reg 39 (3) of LODR |
|
PDF 368 KB |
17 Apr 2023 |
Intimation under Reg 39 (3) of LODR |
|
PDF 417 KB |
23 Mar 2023 |
Outcome of Postal Ballot |
|
PDF 3.3 MB |
20 Mar 2023 |
Intimation under Reg 39 (3) of LODR |
|
PDF 432 KB |
14 Mar 2023 |
Intimation pursuant to Regulation 31A of SEBl Listing Regulations |
|
PDF 458 KB |
24 Feb 2023 |
Strides flagship facility in Bangalore receives USFDA inspection closure |
|
PDF 389 KB |
23 Feb 2023 |
Intimation pursuant to Regulation 31A of SEBl Listing Regulations |
|
PDF 532 KB |
16 Feb 2023 |
Intimation under Reg 39 (3) of LODR |
|
PDF 330 KB |
06 Feb 2023 |
Notice of Postal Ballot – January 24, 2023 |
|
PDF 532 KB |
06 Feb 2023 |
Outcome of Extraordinary General Meeting of the Company held on February 6, 2023 |
|
PDF 660 KB |
06 Feb 2023 |
Proceedings of Extraordinary General Meeting of the Company held on February 6, 2023 |
|
PDF 422 KB |
25 Jan 2023 |
Earnings call Audio link Dec qtr |
|
PDF 274 KB |
24 Jan 2023 |
Outcome of Board Meeting – Unaudited Financial Results (Standalone & Consolidated) for the
quarter and nine months ended Dec 31, 2022
|
|
PDF 3.81 MB |
24 Jan 2023 |
Grant of Options under Strides ESOP Plan 2016 |
|
PDF 272 KB |
23 Jan 2023 |
Earnings call intimation_Dec qtr |
|
PDF 565 KB |
20 Jan 2023 |
Completion of the WHO PQ inspection at the Puducherry facility of the Company |
|
PDF 275 KB |
18 Jan 2023 |
Stelis Biopharma’s flagship facility receives EIR from the USFDA on the successful closure of its
inspection specific to Drug-Device Combination Products
|
|
PDF 391 KB |
13 Jan 2023 |
Notice of Extraordinary General Meeting scheduled to be held on February 6, 2023 |
|
PDF 499 KB |